NOVAREMED-AG
5.3.2019 18:00:09 CET | Business Wire | Press release
The Board of Directors of Novaremed AG, a Swiss clinical-stage biopharmaceutical company, is pleased to announce the appointment of Nicholas Draeger as the new CEO. Nicholas will assume the role effective immediately. Former CEO and Founder, Eli Kaplan, will take a new role in the company to support the company’s further development of its lead asset and expansion of its drug pipeline.
“We are delighted to welcome Nicholas as the new CEO of Novaremed AG. His extensive experience in building and leading teams will be key to successful further development of Novaremed’s lead asset and the company itself. On behalf of the Board, I like to thank Eli for successfully building Novaremed through the past years and for leading the company through a period of significant change. His extensive knowledge of the lead asset will be an invaluable resource and support for the further development of the company.”, said Harry Welten, Chairman of the Board of Novaremed AG.
Nicholas Draeger, 53, has over 25 years of experience spanning the pharmaceutical, equity brokerage, investment management and processed food industries. He started his pharmaceutical career with research and global business development roles at Roche and Recordati. Following which, he joined Credit Agricole Indosuez Cheuvreux, a leading pan-European broker as Head of Biotechnology research. His healthcare portfolio management roles followed thereafter, first as a Portfolio Manager at BB Biotech and then as a Partner at Adamant BioMedical Investments, two of the leading European healthcare institutional investors. He has been leading as CEO, Nurevas International, a processed food company in Ghana, which he co-founded in 2011. Nicholas holds a BSc in Chemical Engineering from the University of Natal, South Africa, a PhD in BioChemical Engineering from the University of Cambridge, UK and an MBA from Warwick Business School, UK.
“I am delighted to have joined the Novaremed team. I look forward to working with the management team and board to continue to build on the excellent foundations that have been created to date. I would like to thank Eli for having founded Novaremed and helped guide this excellent company to this point.”, said Nicholas Draeger.
Eli Kaplan, Former CEO and Founder of Novaremed AG, commented: “I congratulate Nicholas for his new role and wish him the very best for leading Novaremed forward in successfully achieving its near- and long-term goals.”
Notes to the Editor:
About Novaremed
Novaremed Ltd. was founded in 2008 in Israel and reincorporated as Novaremed AG in Switzerland late 2017. Novaremed is developing NRD.E1, an orally-active small molecule with a differentiated mechanism of action for the treatment of Diabetic Neuropathic Pain (DPN). In a Phase 2a Proof of Concept study, NRD.E1 showed clinically relevant reduction in patient reported pain. Novaremed is currently preparing for a global Phase 2b study in DPN, expected to start in Q4 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005776/en/
Contact:
Subhasis Roy, Chief Operating Officer Tel: +41 79 2075715 Email: subhasis.roy@novaremed.com Web: www.novaremed.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom